Stop Superbugs Act
- Sponsor
- Sen. Hassan, Margaret Wood [D-NH]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Aug 4, 2026
Bottom line
The 'Stop Superbugs Act' aims to enhance and streamline clinical research on antibiotic resistance by directing a federal grant to an existing leadership group and authorizing necessary funding.
What it actually does
This bill mandates the Director of the National Institute of Allergy and Infectious Diseases (NIAID) to award a competitive grant to the Antibiotic Resistance Leadership Group (ARLG). The grant's purpose is to establish and facilitate a clinical research network focused on antibiotic resistance, with specific directives to improve participant recruitment, conduct community outreach, integrate diagnostics with pharmaceuticals in trials, and develop patient-reported outcomes. It authorizes the appropriation of such sums as necessary to fund this initiative.
Proponents argue
Proponents argue that this bill is a crucial step in combating the growing public health threat of antibiotic-resistant bacteria, often referred to as 'superbugs.' They contend that by supporting a dedicated clinical research network through an established entity like the ARLG, the nation can accelerate the development of new treatments and diagnostics, improve trial efficiency, and ensure that research effectively addresses patient needs and community engagement.
Opponents contend
Potential critics might argue that while the goal of combating antibiotic resistance is laudable, specifically directing a competitive grant to a single entity like the ARLG, even if competitive, could limit the broader scientific community's participation or stifle innovation from other promising research groups. Concerns could also be raised about the open-ended 'such sums as may be necessary' authorization, which provides no clear fiscal ceiling.
The bill is very short and straightforward, making it highly accessible for any reader to understand its core provisions quickly.
Section 2(a)
Competitive Grant for Antibiotic Resistance Clinical Research Network
This section requires the Director of the National Institute of Allergy and Infectious Diseases (NIAID) to provide a competitive grant to the Antibiotic Resistance Leadership Group (ARLG). The grant's objective is to establish and operate a clinical research network dedicated to studying antibiotic resistance. The network must specifically focus on four key areas: quickly enrolling participants in clinical trials, reaching out to communities for trial recruitment, integrating diagnostic tools with new pharmaceutical treatments during trials, and incorporating patient feedback into research outcomes.
Supporters argue
Supporters argue that directing this grant to the ARLG leverages an established and recognized leader in antibiotic resistance research, ensuring efficient deployment of resources and expertise. The specified focus areas address critical bottlenecks in clinical trials, promising faster development of new therapies and better patient engagement, which are essential for tackling this urgent public health crisis.
Critics contend
Critics might contend that while the ARLG is a capable organization, mandating a grant specifically for them, even if competitive, could limit the potential for other innovative research groups to lead such a crucial national effort. Some may also argue that the specific focus areas, while important, might inadvertently narrow the scope of research or overlook other critical aspects of antibiotic resistance.
Tradeoffs
This provision balances the efficiency of working with an established leader (ARLG) against the potential for broader competition and diverse approaches. It also prioritizes specific operational improvements in clinical trials, which could accelerate development but might divert resources from other fundamental research questions.
Section 2(b)
Authorization of Appropriations
This subsection authorizes the appropriation of 'such sums as may be necessary' to fund the grant and activities described in subsection (a). This means that Congress is permitted to allocate money for this program in future appropriations bills, but this bill itself does not directly provide the funding. The actual amount of funding will depend on subsequent legislative decisions.